Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma

Leukemia

Volumn 18, Issue 10, 2004, Pages 1705-1710

  Wlodarska, Iwona ^a   Meeus, P ^a,b   Stul, M ^a   Thienpont, L ^b   Wouters, E ^b   Marcelis, L ^c   Demuynck, H ^c   Rummens, J L ^d   Madoe, V ^d   Hagemeijer, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b OLV HOSPITAL   (Belgium)

^c Heilig Hart Ziekenhuis   (Belgium)

^d VIRGA JESSE HOSPITAL   (Belgium)

Author keywords

BCL1; CCND1; CD5; Cyclin D1; Mantle cell lymphoma; t(11; 14); Variant translocation

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CASE REPORT; CHROMOSOME 11Q; CHROMOSOME 14Q; CHROMOSOME 2P; CHROMOSOME MAP; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 2; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MANTLE CELL LYMPHOMA; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOMATOLOGY;

EID: 6344270200     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403459     Document Type: Article

References (31)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
2. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991; 88: 9638-9642.
3. Koduru PR, Offit K, Filippa DA. Molecular analysis of breaks in BCL-1 proto-oncogene in B-cell lymphomas with abnormalities of 11q13. Oncogene 1989; 4: 929-934.
4. Brito-Babapulle V, Ellis J, Matutes E, Oscier D, Khokhar T, MacLennan K et al. Translocation t(11;14)(q13;q32) in chronic lymphoid disorders. Genes Chromosomes Cancer 1992; 5: 158-165.
5. Oscier DG, Matutes E, Gardiner A, Glide S, Mould S, Brito-Babapulle V et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol 1993; 85: 487-491.
6. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994; 84: 3828-3834.
7. Jadayel D, Matutes E, Dyer MJ, Brito-Babapulle V, Khohkar MT, Oscier D et al. Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene. Blood 1994; 83: 3664-3671.
8. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640-5645.
9. Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol 1998; 101: 296-301.
10. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
11. Ruchlemer R, Parry-Jones N, Brito-Babapulle V, Attolico I, Wotherspoon AC, Matutes E et al. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol 2004; 125: 330-336.
12. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-1583.
13. Komatsu H, Yoshida K, Seto M, Iida S, Aikawa T, Ueda R et al. Overexpression of PRAD1 in a mantle zone lymphoma patient with a t(11;22)(q13;q11) translocation. Br J Haematol 1993; 85: 427-429.
14. Komatsu H, Iida S, Yamamoto K, Mikuni C, Nitta M, Takahashi T et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood 1994; 84: 1226-1231.
15. Coignet LJ, Schuuring E, Kibbelaar RE, Raap TK, Kleiverda KK, Bertheas MF et al. Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization. Blood 1996; 87: 1512-1519.
16. Vaandrager JW, Schuuring E, Zwikstra E, de Boer CJ, Kleiverda KK, van Krieken JH et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 1996; 88 1177-1182.
17. Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002; 98: 470-474.
18. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 1992; 29: 193-203.
19. ISCN. In: Mitelman F (ed). An international System for Human Genetic Nomenclature. Basel: Karger, 1995.
20. Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. The biology and cytogenetics of multiple myeloma. Rev Clin Exp Hematol 2002; 6: 276-300.
21. Cario G, Stadt UZ, Reiter A, Welte K, Sykora KW. Variant translocations in sporadic Burkitt's lymphoma detected in fresh tumour material: analysis of three cases. Br J Haematol 2000; 110: 537-546.
22. Dyer MJ, Zani VJ, Lu WZ, O'Byrne A, Mould S, Chapman R et al. BCL2 translocations in leukemias of mature B cells. Blood 1994; 83: 3682-3688.
23. Martinez-Climent JA, Vizcarra E, Sanchez D, Blesa D, Marugan I, Benet I et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001; 98: 3479-3482.
24. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
25. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, non-nodal disease. Blood 2003; 101: 4975-4981.
26. Camacho FI, Algara P, Rodriguez A, Ruiz-Ballesteros E, Mollejo M, Martinez N et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003; 101: 4042-4046.
27. Kienle D, Krober A, Katzenberger T, Ott G, Leupolt E, Barth TF et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003; 102: 3003-3009.
28. Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003; 34: 1030-1034.
29. Walsh SH, Thorselius M, Johnson A, Soderberg O, Jerkeman M, Bjorck E et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003; 101: 4047-4054.
30. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
31. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.